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Background: Cardiac resynchronization therapy (CRT) is an established 
treatment modality for moderate to severe heart failure (HF) but 30–40% of 
patients treated with CRT do not experience clinical improvement. Purpose: the 
aim of this study was to identify predictors of response to CRT, in two different 
definitions of responders, by using the cardiopulmonary exercise testing (CPET) 
before CRT implantation. In definition A, responders were defined as ≥15% 
improvement in left ventricular ejection fraction (LVEF); in definition B combined 
parameters were defined as ≥5% improvement in LVEF and ≤1 level NYHA 
classification. Methods: this is a prospective observational study of 15 HF 
patients undergoing CRT. Clinical CPET and echocardiography assessment 
using standard methods were performed at baseline and 5 months. Results: 
the number of patients classified as responders in definition A was 9 (60%) and 
6 (40%) as non-responders; the number of responders in definition B was 11 
(73.3%) and 4 (26.7%) as non-responders at 5 months after CRT. The 
responders according to definition A did not present any statistically significant 
difference. According to definition B, the heart rate (HR) response during CPET 
was higher in non-responders: HR peak (157±13bpm vs. 118±18bpm, p<0.05) 
and HR recovery at minute 3 (54±13bpm vs. 31 ± 14bpm, p<0.05). Overall, the 
responders were older (68±9years vs. 55±9years, p<0.05). Conclusions: 
baseline measurements of CPET may be utilized to identify patients that benefit 
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Approximately 1–2% of the adult population in the western world has heart 
failure (HF), with the prevalence increasing sharply from 1% in 40-year-old 
individuals to 10% above the age of 75 years1. There are many causes of HF, 
and these vary in different parts of the world. The overall prevalence of HF in 
Portugal was slightly higher than other European studies2. The HF prevalence 
increases markedly with age in both sexes and tends to be slightly higher in 
men up to the age of 70. In women, it continues to increase with age and 
becomes greater than the prevalence for men in the age group of 70–79 years 
old3. 
HF is the leading cause of death and hospitalization in most Western 
countries in patients over 65 years of age4. In recent years, cardiac pacemakers 
have been modified in an effort to correct ventricular dyssynchrony. This 
treatment is referred to as cardiac resynchronization therapy (CRT). 
CRT has been used extensively over the last years in the therapeutic 
management of patients with end-stage HF5. The CRT, delivered via atrial-
synchronous biventricular pacing, has emerged as an effective treatment for 
moderate-to-severe HF patients with ventricular dyssynchrony. At present, the 
selection criteria include moderate to severe HF (New York Heart Association 
functional class III or IV), left ventricular ejection fraction ≤ 35%, and wide QRS 
complex (>120 ms)5. However, current guidelines do not adequately identify 
responders to CRT; approximately 30% to 40% of patients treated with CRT do 
not respond or improve with treatment6. The identification of non responders to 
CRT may be also of clinical interest. This therapy requires high costs and has 
potential related complications that may be avoided in patients who will not, for 
an instance, have clinical benefit7. 
Predicting whether a patient will benefit, or respond, to CRT has been the 
focus of more than 500 publications during the last 5 years. However, the 
definition of responder to CRT varies widely between studies, and numerous 
criteria to define a positive response to CRT exist in the literature6, 8. 
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Improvement in clinical end points (symptoms, exercise and functional 
capacities, quality of life) and echocardiography end points (systolic function, 
left ventricular size, mitral regurgitation) have been reported after CRT, with a 
reduction in hospitalizations for decompensated HF and an improvement in 
survival5, 7, 9-16. However, detailed analysis of improvement in functional capacity 
after CRT is still lacking12. 
Cardiopulmonary exercise testing (CPET) with respiratory gas analyses is a 
standardized approach for objectively documenting functional capacity17 that 
provides noninvasive objective measures for cardiopulmonary reserve and is 
thus suitable for evaluation, risk stratification and control of treatment effects18. 
Peak oxygen consumption (VO2peak) measured during maximal exercise 
testing provides an objective assessment of functional capacity in patients with 
HF and an indirect assessment of cardiovascular reserve. Previous studies 
have suggested that this measurement is a good short-term predictor of 
mortality19. 
Mancini et al.19, Stelken et al.20 and others observational studies21, 22 have 
demonstrated that the short-term prognosis of patients with a VO2peak ≤ 14 
kg/ml/min is markedly impaired compared with heart transplant patients 
followed up for a similar duration. 
Patients with a baseline VO2peak < 14 ml/kg/min regularly benefit from CRT 
during the first year of treatment23. These findings have not yet been included in 
the current Guidelines for the Implantation of Permanent Pacemakers by the 
ACC/AHA/ NASPE24, while the German “Statement on cardiac 
resynchronization”25 already recommends a baseline VO2peak < 14 ml/kg/min as 
one criterion to indicate CRT. 
 
2.2 OBJECTIVES’ OF THE STUDY 
 
The aim of this study was to identify predictors of response to CRT, in two 
different definitions of responders, by using the CPET before CRT implantation. 
The secondary aim of this study was to evaluate VO2peak, VE/VCO2 slope, 
HR response, anaerobic threshold, NYHA class symptom and LVEF, 
immediately before and 5 months after CRT implantation, to study the 
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ventilatory and haemodynamic response evolution and to assess improvement 
in functional and echocardiography variables. 
In this study, the criteria used to define responders to CRT will be 
considered according to 2 different ways found in the literature review. The first 
way of defining responders is based on echocardiography, through the increase 
of LVEF ≥ 15%26, 27. The second way combines echocardiography and clinical 
setting, through the increase of LVEF ≥ 5% and decrease of NYHA ≥ 1, 
respectively28. 
The relevance of this study is to have reproducible inclusion criteria 
parameters that are crucial for a reliable evaluation of the CRT response. 
Considering the high costs and non responder rates of about one-third of the 
patients, a careful selection of patients prior to CRT is crucial. 
This document is composed by five chapters; each chapter will have a short 
introduction that explains the theme in question. The theme’s presentation (2) is 
a brief description of the state of knowledge of the main theme. The emerging of 
some questionable issues justifies the purpose and objectives of the present 
study and also the study’s limitation. The literature review (3) comes to specify 
the theoretical background followed by the methodology section (4) that 
describes all the steps of this study, from the sample selection and the 
instruments used to collect data to the statistical analysis. The results and 
discussion are considered together for better critical analysis and evaluation of 
the different variables. In the same chapter, it will be presented the future 





The following limitations were considered: 
1. Small study sample size, limited power to detect significant differences in 
the studied parameters.  
2. Peak SBP measurements during exercise are also influenced by 
technique and sampling frequency. Vasodilator drug therapy may also 
limit exercise SBP response. In the present study, not all 
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antihypertensive drug therapy data was collected at the time of exercise 
testing.  
3. The fact that these patients have skeletal muscle pathology as a major 
contributor to exercise intolerance, fatigue, and exertional dyspnea in 
chronic heart failure, restricts the clinical value of the variables of the 
CPET, like VAT and VO2/VCO2 slope.  
4. In most patients only one baseline exercise test was performed, and an 
improvement in exercise time and VO2 may occur with familiarization of 
the technique29. Other potential limitations of VO2peak also must be 
considered. 
5. There are many different methods to define a positive response to CRT 
in the literature and poor agreement was found amongst them. 
Nevertheless, in this study two criteria to assess different types of 
responders were considered. For the reasons previously mentioned, a 
question can be formulated for continuing the research work to find an 
answer: which method should be used in the future to determine whether 




3 LITERATURE REVIEW 
 
3.1 HEART FAILURE 
 
Chronic heart failure (CHF) is a clinical syndrome resulting from a structural 
or functional cardiac disorder and it could be defined by systolic dysfunction, 
diastolic dysfunction, or both which usually involves an assessment of the 
patient’s ejection fraction30. It usually begins after an initial event that produces 
a decline in pumping capacity of the ventricle. This syndrome manifests 
primarily as dyspnea, fatigue, fluid retention, such as pulmonary congestion or 
ankle swelling, and decreased exercise tolerance31. 
Systolic dysfunction and diastolic dysfunction, both describe an abnormal 
mechanical property, while systolic heart failure (SHF) and diastolic heart failure 
(DHF) describe a clinical syndrome30.  
The SHF reflects a fundamental weakness of the pump and thus the inability 
to deliver sufficient cardiac output at an adequate mean arterial pressure. The 
failing heart often exhibits both major decrements in resting systolic function 
and also limitations of systolic reserve required for individuals to perform normal 
activities of daily living and exercise. The systolic dysfunction refers to impaired 
ventricular contractions due to the loss of myocardium secondary to myocardial 
infarction or loss of contractility, and the underlying mechanisms are numerous. 
Patients with HF and a low left ventricular ejection fraction (LVEF), usually < 
40–45%, are classified as having systolic dysfunction15, 30. 
In contrast, in patients with DHF, the dysfunction occurs when the ventricular 
chamber is unable to accept an adequate volume of blood during diastole and 
the sufficient volumes to maintain an appropriate stroke volume at rest and 
during exercise. The functional abnormalities leading to DHF includes abnormal 
ventricular relaxation and filling, decreased LV suction, and/or an increase in 
ventricular stiffness. Diastolic dysfunction refers to a condition in which 
abnormalities in mechanical function are present during diastole. It is 
characterized by an increased resistance to the filling of one or both ventricles, 
elevated diastolic pressure in the ventricles, and reduced ventricular 
compliance. Patients with symptoms and exam findings consistent with HF, but 
with a preserved ejection fraction are often said to have diastolic dysfunction4,32. 
12 
 
The demographic characteristics present in patients with DHF differ 
significantly from those with SHF. Patients with DHF are older, often female, 
have hypertensive heart disease, and are less likely to have ischemic heart 
disease compared to patients with SHF. Diastolic dysfunction is estimated to be 
the principal etiology in 40% or more of the estimated 500.000 new cases of HF 
each year30. 
HF is a final common pathway of all diseases of the heart and is a major 
cause of morbidity and mortality. It is a complex syndrome with numerous risk 
factors and determinants of outcomes. Approximately 4.9 million Americans 
carry the diagnosis of HF33 and about 550.000 new cases occur each year in 
the USA34. Reports from several countries suggest that approximately 1–2% of 
the total healthcare budget is spent on the management of HF35. 
In Portugal the overall prevalence of HF was markedly higher than other 
European studies and increases sharply with age2. HF with LV systolic 
dysfunction is more frequent in males below the age of 80 years and with 
preserved LV systolic function affects mainly older females3. 
HF remains a large medical and epidemiological problem31, and the number 
of HF hospitalizations has risen more than a million per year over the past 
decade, accounting for at least 20% of all admissions for persons older than 65 
years16. 
At the cellular level, is caused by changes in the biology of the cardiac 
myocyte together with a progressive loss of cardiac myocytes. The loss of 
myocytes may be focal (e.g., myocardial infarction), or diffuse (e.g., viral 
infection, hemodynamic overload, genetic abnormalities). 
Thus HF is the common clinical syndrome caused by any of a diverse group 
of injurious stimuli sufficient to produce myocardial insufficiency36. Abnormal 
impulse generation and propagation is frequently observed in these patients. 
Both functional and structural alterations (cardiac remodeling) are responsible 
for such abnormalities32. 
Cardiac remodeling commonly refers to persistent changes in the properties 
of myocardium in response to abnormal external stresses. Although most 
notably cardiac remodeling occurs in the setting of structural heart diseases 
such as myocardial infarction, hypertrophy, and HF, it may also occur in the 
absence of anatomic dysfunction, as is the case during abrupt changes in heart 
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rate and/or activation sequence. Indeed, remodeling is a prominent feature of 
atrial fibrillation and flutter, ventricular pacing or intrinsic conduction delays and 
sustained tachycardia32. 
Left bundle branch block (LBBB) results from block or conduction delays in 
any of several sites of the left-sided intraventricular conduction system, 
including the main left bundle branch or its subdivisions or, less commonly, 
within the fibers of the distal His bundle. The result is an abnormal and slow 
pattern of electrical activation within the LV due to conduction through the 
working myocardium. 
LBBB usually appears in patients with underlying heart diseases, typically in 
patients with dilated cardiomyopathy of any etiology32. 
It has long been recognized that discoordinate cardiac contraction itself 
reduces the systolic performance of the chamber, and recent developments in 
therapies to resynchronize contractions have shown this to be a valuable target 
for HF treatment. Conduction disease at or above the atrial ventricular (AV) 
node affects chronotropic competence and effective preload (and left atrial 
pressure). Both short and excessively long AV delays the reducing of net LV 
filling.  LBBB induces discoordinate contraction. Cardiac discoordination 
induced by LBBB or right ventricular pacing depresses systolic function, 
increasing the end-systolic volumes at a given pressure, prolongs isovolumic 
relaxation, and has been coupled to the widening of the QRS complex. 
Significant progress has been made to identify the major risk factors and the 
population patterns of HF and associated trends. However the prognosis 
remains poor, with mortality data comparable with data from the worst forms of 
malignant disease. Therefore, it deserves adequate planning for investigation, 
education, prevention and treatment. 
 
3.2 CARDIAC RESYNCHRONIZATION THERAPY 
 
CRT improves HF outcomes37 and has been used extensively over the last 
years in the therapeutic management of patients with end-stage HF5. 
Approximately 40 years ago, the first descriptions of the short-term 
haemodynamic effects of left or of simultaneous right and left ventricular 
stimulation were published38-40. Cardiac pacing as an adjunct therapy for HF 
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began to be the subject of scientific research at the start of the 1990’s. The CRT 
began in 1994, when Cazeau et al.41, in France, and Bakker et al.42, in 
Netherlands, described the first cases of atrio-biventricular pacemakers 
implanted in patients with severe CHF and no conventional indication for 
cardiac pacing. 
CRT is an effective treatment for patients with moderate to severe HF and 
LV systolic dysfunction if they have a prolonged QRS interval on the surface 
electrocardiogram suggesting cardiac dyssynchrony43, 44. It aims providing 
hemodynamic benefit by correcting an electrical disturbance. 
Both atrioventricular and intraventricular conduction delays further aggravate 
LV dysfunction in patients with underlying cardiomyopathies. Notably, as 
mentioned previously, LBBB alters the sequence of LV contraction, causing wall 
segments to contract early or late, with redistribution of myocardial blood flow, 
non-uniform regional myocardial metabolism, and changes in regional 
molecular processes45.  
Intraventricular dyssynchrony seems to represent a pathophysiological 
process that directly depresses ventricular function, causes LV remodeling and 
CHF. Consequently, it causes a higher risk of morbidity and mortality. Such 
dyssynchrony is apparent on the electrocardiogram as a QRS interval lasting 
more than 120 miliseconds. Some studies have proposed that this 
intraventricular conduction delay may further impair the ability of the failing heart 
to eject blood (shortening of LV filling) and may thus enhance the severity of 
regurgitant flow through the mitral valve11, 46. 
The clinical effects of long-term CRT have been evaluated in a large number 
of randomized multi-centre trials with crossover or parallel treatment 
assignment 47-53 using CRT pacemakers (CRT-P) or CRT in combination with 
implantable cardioverter defibrillator (ICD) therapy (CRT-D). However, there are 
some unresolved issues for this device selection, namely whether CRT-D is 
better to reduce risk of death than CRT alone.  
CRT-P is a therapy that differs from the classical cardiac pacing, as: 1) all 
CRT patients have advanced HF; 2) the rationale of atrio-biventricular pacing is 
electromechanical resynchronization and not correction of bradycardia (most of 
the patients do not have conventional pacing indications); 3) the devices are 
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more sophisticated, with an additional lead; and 4) a significant number of the 
patients have an ICD indication46. 
The typical CRT patient is a high-risk patient with an increased risk for 
sudden cardiac death (SCD) that is significantly reduced54 but probably not 
optimally prevented by CRT alone. Three randomized, prospective, controlled 
trials have shown the efficacy of the stand-alone ICD in the primary prevention 
of SCD in patients with a history of previous myocardial infarction and 
depressed ejection fraction55-57. Two relevant randomized, controlled trials have 
demonstrated that HF patients with LV dysfunction treated with an ICD have a 
reduced risk of death, regardless of the aetiology52, 58. 
There has been a substantial increase in implantation rates for CRT across 
Europe, although with marked differences amongst countries59-61. Meta-
analyses were also published9, 10, 62, 63, suggesting that the most efficacious 
option in patients with HF and LVEF would be a CRT-D. 
Therefore, it is strongly recommended that the choice of the most 
appropriate device (whether CRT-P or CRT-D) for a patient be based upon 
careful evaluation of the following two considerations: first, the patient’s 
expectation of survival, which, when considering an ICD, should exceed 1 year; 
and the second point, relates to health care logistical constraints and cost 
considerations. 
Pacing in HF may be achieved by means of two different pacing modalities, 
biventricular pacing or LV pacing alone.  Biventricular pacing has been 
extensively studied and most widely used but LV pacing may be acceptable in 
certain patients. Although indications for LV pacing must still be clearly defined, 
there is more evidence suggesting that applying LV pacing is comparable with 
the biventricular mode in selected HF patients presenting LBBB or 
echocardiographic evidence of significant mechanical delay at the level of the 
LV lateral wall64-69.  In selected cases who present LBBB, conventional CRT 
indication, advanced age, and/or important comorbidities, without a 
bradycardiac indication for a pacemaker, in whom an improvement in quality of 
life is sought, it may be reasonable to consider LV pacing alone. 
The development of devices that make use of atrial-synchronized 
biventricular pacing to coordinate right and left ventricular contraction have 
suggested, in recent studies, that short and long term CRT can improve cardiac 
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function, exercise capacity, functional class, VO2peak, hemodynamic measures, 
and quality of life score5, 7, 11-15. It also reduces hospital readmissions and 
decreases mortality10,13,14,37. These benefits primarily occur due to an 
improvement in the central cardiovascular function of the heart.  
A recent study, called CARE-HF (Cardiac Resynchronization-Heart Failure), 
has focused on the effect of CRT on morbidity and mortality in HF patients53. 
The conclusion was that CRT improves symptoms, the quality of life and 
reduces complications and the risk of death. It subsequently demonstrated a 
clear survival benefit after the CRT compared to optimized medical therapy. 
A reduction in hospitalizations was observed in the Multisite Simulation in 
Cardiomyopathies (MUSTIC) and Multicenter InSync Randomized Clinical 
Evaluation (MIRACLE) trials47, 70. 
The Comparison of Medical Therapy Pacing and Defibrillation in Heart 
Failure (COMPANION) trial demonstrated a reduction in the composite end 
point of all-cause mortality or hospitalization during the 16 months of follow-
up52. 
 Current guidelines do not adequately identify responders to CRT; 
approximately 30% to 40% of patients treated with CRT do not respond to 
treatment or improve subsequently. The definition of response to CRT varies 
widely between studies, and numerous criteria to define a positive response to 
CRT exist in the literature6. 
 The response to CRT can be measured in terms of symptomatic response 
or clinical outcome, or both71. The symptomatic response is typically assessed 
by quantifying the change in left ventricular ejection fraction26, 27, 72, 73 or left 
ventricular end systolic volume (LVESV)73-75 3 to 6 months after CRT 
implantation. The clinical response is assessed with the increase in the distance 
walked in 6 minutes13 or  improvement in New York Heart Association functional 
class (NYHA)73, 76 3 to 6 months after CRT implantation (table 1). Some studies 
have defined response to CRT as a combination of several clinical measures72, 








The lack of improvement with CRT can be due to many factors including the 
placement of the LV pacing lead in an inappropriate location, the absence of 
electrical conduction delay or mechanical dyssynchrony despite wide QRS 
complexes, and possibly failure to optimize the CRT settings after device 
implantation79.  
The reverse left ventricular remodeling or cardiac remodeling, as explained 
previously, has been demonstrated with drugs that are known to benefit patients 
with HF, such as angiotensin converting enzyme inhibitors and beta-blockers. 
Reductions in LVESV appears to be the most useful measure of reverse 
remodelling80. 
 Reverse LV remodeling is a promising surrogate outcome measure for the 
CRT.  Yu et al.81 explored the value of reverse LV remodeling in discriminating 
prognostic responders and non responders to CRT in a study of 141 patients, in 
which a reduction in LVESV ≥ 9.5% 3 to 6 months post-implantation was 
identified as a predictor of all-cause (p = 0.0003) and cardiovascular (p < 
0.0001) mortality.  
 This study has a specificity of 69%, which means that 31% of patients, that 
do not benefit prognostically, are wrongly classified as responders. 
Furthermore, in this study they found no relationship between reduction in 
LVESV and changes in NYHA class, 6 minute walk distance or quality of life 
score after CRT. 
Likewise, Ypenburg et al.82 found similar improvement in NYHA class, 
quality of life score, and 6 min walk distance in patients exhibiting ≥ 15% 





No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 
palpitation or dyspnea. 
Class II 
Slight limitation of physical activity. Confortable at rest, but ordinary physical activity results 
in fatigue, palpitation, or dyspnea. 
Class III 
Marked limitation of physical activity. Confortable at rest, but less than ordinary activity 
results in fatigue, palpitation, or dyspnea. 
Class IV 
Unable to carry on any physical activity without discomfort. Symptoms at rest. If any 
physical activity is undertaken, discomfort is increased. 
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reduction in LVESV compared with those exhibiting a reduction in LVESV of < 
14%.  
In a review, Foley et al. group numerous studies that have shown significant 
reduction in LVESV after CRT71. Such reductions are evident as early as 1 
month post-implantation83, and are sustained at 29 months53.  
 





1. ↑ LVEF ≥ 5%
72, 73
 
2. ↑ LVEF ≥ 15%
26, 27
 
3. ↓LVESV ≥ 10% and did not die of progressive HF within 6 months 
78, 84
 
4. ↓LVESV > 15%
73-75, 85
 
5. LVESV < 115% of baseline
86
 
6. ↓ LVESVI > 15%
87
 
7. ↓LVEDV > 15%
73
 




9.  ↓NYHA ≥ 1 
73, 76, 90, 91
 
10. ↓NYHA ≥ 1 and did not die of progressive HF within 6 months
92
 
11. ↓NYHA ≥ 1 and ↑ 6MWD ≥25%
72
 








14. (↓NYHA ≥ 1 or ↑VO2max > 10% or ↑6MWD >10% ) and alive, no 
hospitalization for decompensated HF
93
 
15. Two of 3:
74
 
a. ↓NYHA ≥ 1 
b. ↑6 MWD ≥ 50m 
c. ↓QOL ≥ 15 




17. (↑LVEF ≥ 5% or ↑6MWD ≥ 30m) and (↓NYHA ≥1 or↓ QOL ≥ 10)
28
 




























↑ indicates increase; LVEF, left ventricular ejection fraction; ↓, decrease; HF, heart failure; LVESV, left 
ventricular end-systolic volume: LVESVI, LVESV indexed by body surface area; LVEDV, left ventricular 
end-diastolic volume; NYHA, New York Heart Association functional class; 6MWD, 6-minute walk distance; 
VO2max, oxygen consumption at peak exercise, and QOL, quality-of-life score. 
If the authors did not specify whether death was considered a nonresponse, then it was assumed that 




Fornwalt et al.6 collected seventeen different primary response criteria in the 
26 most-cited publications on predicting response to CRT (table 2). Eight of 
these seventeen response criteria were based on echocardiography, eight were 
based on clinical measures, and one criterion was based on a combination of 
both echocardiographic and clinical measures. The percentage of patients 
defined as having a positive response to CRT ranged from 32% to 91% for the 
15 response criteria. 
The reasons for a lack of response to CRT are not well known7, 13, 14, 37. So 
far, better characterization of patients who will respond to CRT has been the 
main focus of ongoing research. 
The identification of non responders to CRT may be also of interest. This 
therapy requires high costs and potential implantation related complications that 
may be avoided in patients who won’t have clinical benefit. Current inclusion 
criteria may not be accurate enough to differentiate patients who will or will not 
respond to CRT. Other pathophysiologic factors such as HF etiology, LV 
dimensions and function, mitral regurgitation, LV dyssynchrony, position of LV 
pacing lead, and extent/location of myocardial scar have also shown to 
influence CRT response7.  
CRT was associated with increased total costs when compared with 
standard medical treatment. Over a mean follow-up of 29.6 months in CARE-
HF94, the mean €4316 overcost was mainly attributable to the device itself, with 
an estimated cost of €5825. 
The mean incremental cost-effectiveness ratio per life year gained was €29 
40094  and $28 10095 with CRT-P and $46 700 with CRT-D95. These data 
suggest that the clinical benefits of CRT are economically viable and can be 
achieved at a reasonable cost in most European countries. 
Long-term treatment with CRT-P appears cost-effective compared with 
medical therapy alone. From a life-time perspective, assuming a reasonable life 
expectancy when receiving effective treatment for HF, CRT–D may also be 
considered cost-effective when compared with CRT-P and medical therapy96. 
The 2007 ESC/EHRA Guidelines for Cardiac Pacing46, the 2008 ESC Heart 
Failure Guidelines31, and the 2008 ACC/AHA/HRS Guidelines for Device 
Therapy97 provide class I A recommendation for CRT treatment with or without 
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an ICD function in patients with QRS width ≥ 120 ms, LVEF ≤ 35% and NYHA 
functional class III and IV. Those are the current inclusion criteria for CRT.  
ECG recording should be taken to know the PR interval, QRS duration and 
morphology, and underlying rhythm to choose the most appropriate device. 
There is strong evidence that patients with prolonged QRS duration (≥120/ ≥130 
ms) show worse prognosis but the impact of QRS duration to predict response 
to CRT is still unclear98. 
Another important diagnostic tool is echocardiography evaluation for precise 
assessment of ventricular dimensions, presence of mitral regurgitation, the 
estimation of the LVEF (≤ 35%) and diagnosis of ventricular dyssynchrony. 
Lafitte et al.99 concluded that a multiparametric echocardiographic strategy 
based on the association of conventional criteria is a better indicator of CRT 
response than the existing single parametric approaches. Nevertheless, many 
currently used echocardiographic parameters failed to improve responder 
identification. There is no consensus about which echocardiographic 
parameters may best determine baseline dyssynchrony and which of these can 
predict response to CRT72, 85, 87, 89, 98, 100-108. 
Besides ECG and echocardiographic parameters, cardiopulmonary exercise 
testing (CPET) is an important criterion for screening patients undergoing 
CRT18. 
 
3.3 CARDIOPULMONARY EXERCISE TESTING 
 
CPET and the 6-minute walk are the most common modalities for evaluating 
the functional capacity of patients with HF. 
The 6-minute walk is usually used as an alternative to CPET, as it evaluates 
low-level or submaximal work and is more compatible with activities of daily 
living. This test and the NYHA classification may be helpful for assessing 
patient’s physical ability. Many clinical trials have used the 6-minute walk test to 
classify patients with HF into syndrome severity categories. A significant 
correlation between distance walked during 6 minutes and survival is noted. A 
total distance walked of less than about 300 meters in a study carried an annual 
mortality risk of 11%, in contrast to 4% among patients who could walk more 
than about 450 meters109. 
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CPET is used to evaluate maximal exercise capacity, for prognostic 
stratification, and for staging for possible cardiac transplantation. There is 
different exercise testing protocols in which the workload is progressively 
increased during the test, either on a bicycle or a treadmill. The selection of a 
particular protocol should be based on the experience of the testing physician, 
on the physical ability of the patient, and on the availability of the facility where 
the test is being performed. Exercise testing of patients with HF is supported by 
the American Heart Association for clinical and research application36. 
The CPET has some advantage compared to the traditional exercise testing. 
Both of the tests are ECG monitoring however, the CPET used gas exchange 
analysis, which can provide directly the peak VO2, a measure of coupling 
between central pulmonary gas exchange, cardiac output, and peripheral 
oxygen delivery to and use by skeletal muscle36.  
Even so, this testing has some implications like time-consuming, expensive 
(it requires specialized equipment for gas exchange, coupled to ECG), and 
requires great skill in cardiopulmonary physiology. 
In spite of these limitations, the measurements of carbon dioxide production 
and oxygen consumption during this test can provide numerous additional data 
that have both diagnostic and prognostic information, such as the ratio of 
volume of expired gas to carbon dioxide production (VE/VCO2), ventilatory 
threshold, and respiratory exchange ratio. 
 
HEART RATE RESPONSE 
 
There is yet no consensus about the value of the resting heart rate (HR) 
relative to measure the risk to develop cardiovascular diseases and mortality. 
Some authors defend that HR is not recognized as a factor for 
cardiovascular risk assessment or risk reduction in U.S. and European 
guidelines. A review of resting HR in cardiovascular disease, leaves some 
doubts that HR is a risk factor for cardiovascular mortality, independent of 
currently accepted risk factors and other potentially confounding demographic 
and physiological characteristics. It has been difficult to determine whether 
modulation of HR can beneficially alter risk; currently available interventions that 
lower HR, such as beta-blockers, certain calcium channel blockers, and 
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physical conditioning have multiple additional actions. Nonetheless, improved 
HR is important and potentially beneficial for patient care110. 
More recently, there has been a study with patients with left ventricular 
dysfunction and a recent myocardium infarction or HF showed that resting HR 
was independently associated with increased risk of overall mortality over a 10 
year follow-up period. The results suggest that the prognostic importance of 
resting HR is stronger in patients with myocardium infarction compared to 
patients with HF, especially in the short term111. 
The immediate response of the cardiovascular system to exercise is an 
increase in HR due to a decrease in vagal tone. This increase is followed by an 
increase in sympathetic outflow to the heart and systemic blood vessels. During 
dynamic exercise, HR increases linearly with workload and VO2. Heart rate will 
reach a steady state within minutes during low levels of exercise and at a 
constant work rate. As workload increases, the time necessary for the HR to 
stabilize will progressively lengthen. The HR response to exercise is influenced 
by several factors such as age, deconditioning, body position, type of exercise, 
and various states of health and therapy, including heart transplant29, 112. The 
HR peak is the highest value of the heart rate or pulse rate which can be 
attained and measured during incremental exercise. 
HR recovery refers to the deceleration of the HR in early exercise recovery 
in association with vagal tone reactivation. It is the difference between HR at 
peak exercise and after one minute or other time defined of recovery. An 
abnormal value for the recovery of HR was defined as a reduction of 12 beats 
per minute (bpm) or less from the HR at peak exercise113, 114. The increase in 
HR that accompanies exercise is due in part to a reduction in vagal tone. HR 
recovery immediately after exercise is a function of vagal reactivation, a 
decrease of vagal activity is known to be a risk factor for death114. 
Lipinski et al.115 and Tang et al.116 conclude that HR recovery on the first 
minute recovery is a significant predictor of mortality and may provide valuable 
prognostic information for patients with HF or LVSD. HR recovery should be 
evaluated along with VO2, age, HR peak, and other variables to predict mortality 
and may also aid in determining which patients with HF and LVSD will require 
heart transplantation113, 115. Even after adjusting for other exercise derived 
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predictor variables and previously validated HF survival scores, post-exercise 
HR recovery remained an independent predictor of adverse clinical events116. 
Moreover, a recent study concludes that CRT favorably alters the cardiac 
autonomic functions assessed by HR recovery indices117. This effect of CRT on 
cardiac autonomic functions was observed both in responders and in non 
responders. However, the degree of improvement in HR recovery indices is 
correlated with left ventricular reverse remodeling. In the Okutucu et al.117 study, 
the baseline HR recovery indices could not predict response to CRT, 
considering a responder as a decrease of ≥ 15% in LVESV at the 6-month 




Maximum oxygen uptake (VO2max) or peak oxygen uptake (VO2peak) is the 
maximum capacity of an individual's body to transport and use oxygen which 
can be attained and measured during an incremental exercise protocol for a 
specific exercise mode. It can, however, be affected by age, gender, muscle 
mass, aerobic conditioning and medication therapy. It is measured in liters per 
minute, but is often relativised for body mass (ml/kg/min) to allow better 
comparison between individuals of different body size. 
Functional status and cardiac reserve of patients with CHF can be 
objectively characterized by determining exercise tolerance. Particularly 
important is the precise measurement of VO2peak consumption.  
VO2peak is one of the most important independent predictors of mortality and 
hospitalization for patients with HF19, 118. This functional variable represents 
functional effort capacity and is improved significantly by CRT119, 120, but is 
influenced by non-cardiac factors (age, motivation, anaemia and obesity). It has 
become probably the most important test to determine whether ambulatory 
patients are ill enough to list for cardiac transplantation36. 
Mancini et al.19 analyzed if VO2peak can be used to identify ambulatory 
patients in whom cardiac transplantation can be safely deferred. According to 
the study protocol, patients with a VO2peak > 14 ml/kg/min were denied 
transplantation, whereas those with a VO2peak ≤ 14 ml/kg/min were offered 
transplantation. Thus, in spite of similar LVEF, patients with VO2peak < 14 
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ml/kg/min have a far worse prognosis than those with VO2peak >14 ml/kg/min. It 
is important to include in the follow-up of CHF patients the determination of 
VO2peak to establish more effectively the optimal therapeutic strategy
23. Recent 
recommendations for the International Society for Heart and Lung 
transplantation guidelines for CPET were VO2peak ≤ 12.0 ml/kg/min for patients 
receiving beta-blockers and VO2peak ≤ 14.0 ml/kg/min for patients not receiving 
such therapy121. 
An accurate estimation of VO2peak might be underestimated and it is difficult 
to obtain in patients with severe HF.  It is difficult to assess whether a truly 
maximal test was performed and rarely is reach a true plateau of oxygen 
consumption with increasing workloads because of some limitations such as 
peripheral muscle fatigue, motivation or procedural difficulties (selection of an 
appropriate exercise protocol)98, 121. 
HF patients rarely reach a plateau of VO2 with increasing workloads, 
common determinants of a maximal exercise test have been respiratory 
exchange ratio (RER) > 1.1 and reaching an anaerobic threshold. The RER 
rises from a resting value of around 0.7 at rest during exercise. Healthy controls 
achieve a RER at peak exercise of between 1.10 and 1.20 or even higher, 
indicating that anaerobic metabolism is occurring. Such a RER is used as an 
indicator of maximal effort112. Patients with CHF are typically less able to 
exercise to a level with such a high RER, and some CHF patients are unable to 
reach a RER ≥ 1.0. Ingle et al.122  conclude that independent predictors of 
mortality were different in patients with a RER < 1.0 compared to those with a 
RER ≥ 1.0. In CHF patients with a RER < 1.0, traditional prognostic markers 
(VE/VCO2 slope, VO2peak) were not independently predictive of mortality. 
However, a review of studies defining the criteria for VO2peak showed that 6 of 
14 studies used an RER cutoff of 1.0 or 1.05, so these criteria may be too 
stringent. Decisions might also need to be made based on a submaximal 
test121. 
In a study by Auricchio et al.12 patients with peak VO2 > 16 ml/kg/min did not 
show significant cardiorespiratory improvements during CRT. In contrast, a 
study by Piepoli et al.123 showed that patients with a peak VO2 ≤ 7 ml/kg/min did 
not benefit from CRT. A difference of approximately 2 ml/kg/min in VO2peak 
strongly depends on the motivation of the patients. 
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In a recent study Berger et al.98 analyzed the impact of the cardiorespiratory 
functional reserve to predict the response to CRT. Submaximal 
cardiopulmonary treadmill exercise testing prior and 6 months after implantation 
of a CRT device was made. Responders to CRT, defined by a decrease in 
LVESV > 15% showed a significant lower cardiorespiratory reserve at baseline 
(prior CRT) as compared to the non responders.  The conclusion of this study 
was that non responders to CRT showed a more preserved cardiorespiratory 
functional reserve as compared to responders despite similar NYHA 
classification. 
Some authors have used percentage of predictive VO2peak rather than the 
absolute value to stratify risk. In multivariate analysis, 50% or 55% of predicted 
peak oxygen uptake (when the respiratory exchange ratio is greater than 1.10) 
has generally been selected as the most significant predictor of cardiac 
death121. The proposed cutoff point of 50% has been confirmed by Stelken et 
al.20, who showed that in a cohort of 181 HF patients those with an oxygen 
uptake greater than 50% predicted value had a 94% possibility two year survival 
as compared to only 50% survival in patients with an oxygen uptake of below 
50% predicted value. 
Therefore, the percentage of predicted value in clinical reports must be 
interpreted in a patient specific context in view of other comorbidity conditions, 
for example, adjustments have to be made if the patient is taking a beta-
blocker124. 
 
SLOPE OF THE VENTILATORY RESPONSE 
 
VE/VCO2 is calculated during a cardiopulmonary exercise test and is the 
slope of the relationship between minute ventilation (VE) and oxygen uptake 
(VO2) during incremental exercise
125.  The ventilatory response evaluation is not 
influenced by beta-blocker therapy and submaximal exercise. It is well 
recognized that VE/VCO2 slope is measurable at any point during exercise and 
adds significant prognostic value in HF population126.  
In patients with HF an increased ventilator response throughout exercise is 
observed. A VE/VCO2 slope value up to 35 was associated with a one-year 
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mortality rate of 30% in the Corra et al. study127. Francis et al.128 found a two-
year mortality rate of 65% for patients with a value up to 55. 
The VE/VCO2 slope seems to be a better predictor of outcome than VO2peak 
with regard to submaximal effort128. The complementary prognostic value 
especially with the VO2peak is of great interest. Patients with VO2peak < 11 
ml/kg/min and VE/VCO2 slope ≥ 34 are at particularly high risk for 
transplantation or death. Thus, patients with well preserved exercise capacity 
and low VE/VCO2 slope are at low risk for transplantation or death. This 
approach allows high-risk patients to be identified noninvasively and could 
provide guidance for intensified treatment (medical regimen, CRT, exercise 
training and heart transplantation) and monitoring129. 
This parameter should be a routine component of exercise analysis in HF 
population. Consideration should be given to revising clinical guidelines to 




VENTILATORY ANAEROBIC THRESHOLD 
 
In 1991, submaximal exercise parameters such as the ventilatory anaerobic 
threshold (VAT) were introduced to evaluate the cardiopulmonary functional 
reserve. In fact, most activities of daily living do not require maximal effort, so 
submaximal exercise parameters should be used like VAT. 
There is a point during progressive exercise in which lactate accumulation 
caused a nonlinear increase in ventilation. The increase in blood lactate 
concentration during exercise is thought to cause a nonlinear increase in 
ventilation as a result of bicarbonate buffering of excess hydrogen ions from 
lactate in the blood and consequent production of carbon dioxide. The resulting 
hyperventilatory response has been commonly termed the VAT131. 
VAT is assessed by ventilatory expired gas, defined by the exercise level at 
which VE begins to increase exponentially relative to the increase in VO2. 
Nevertheless, VAT cannot be obtained in 25% to 30% of patients with HF 
because of severe deconditioning, early onset of acidosis, and the presence of 








This chapter describes the methodological procedure of the study. In the first 
part, a description of the experimental concept such as the study design and the 
characterization of the sample are presented. In the second part, study 
variables are presented, including the independent and dependent variables 
and how they were evaluated. The statistical treatment of the data of interest to 
the present study was the last task of the procedure to be done. 
 
4.2 STUDY DESIGN 
 
The present study is an observational and analytical prospective cohort 
study. This study design requires a comparative analysis between data 
collected in CPET before and after the implantation of a CRT considering two 
types of criteria to define responders as well an echocardiography and clinical 
consultation to assess the ejection fraction and analyze the NYHA class. 
Data were collected before and after the implantation of a CRT, under the 




The study sample initially included 22 patients from both genders with CHF 
referred to Santa Marta Hospital, Lisbon. From the 22 patients that initially met 
the criteria for enrolment in the study, 7 were excluded for data analysis. 
Therefore, the total sample for this study consisted of 15 patients. 
Patients were excluded for several reasons, such as: having traditional 
exercise testing done after CRT instead of CPET (n=2), missed some variables 
measured from CPET (n=2), missed CPET after CRT before data were 
analyzed (n=2) and CRT not working properly (n=1). 
The study sample receiving CRT based on the following clinical criteria were 
considered for this study: patients presenting severe symptomatic heart failure 
despite optimal pharmacological therapy (NYHA functional Class III or IV), 
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LVEF < 35% and free of exercise-limiting comorbidities such as cerebrovascular 
disease, muskuloskeletal impairment, or peripheral vascular disease. 
All patients were followed-up prospectively at Santa Marta Hospital. Clinical 
status (NYHA class) was assessed at baseline and approximately 5 months 
after CRT. The average time of the echocardiogram performed after CRT was 2 




There are two possible criteria used to classify the CRT response according 
to the literature. The first is defined by an increase of 15% or more of LVEF, 
measured by conventional echocardiography from baseline to follow-up26, 27. 
The second was a combinination of two criteria, defined by clinical and 
echocardiography measures with an increase of 5% or more of LVEF and a 
decrease of 1 or more NYHA class, respectively28. These measures were 
chosen because of their percentage of response rate, the first with 54% and the 
second with 71% of response rate, as seen in table 2, page 18.   
 
4.4 VARIABLES IN STUDY 
 
4.4.1 DEPENDENT VARIABLES 
 
In this study the following dependent variables were considered: in 
echocardiography, the ejection fraction; in the clinical category, the NYHA class; 
and in the CPET the, VO2 peak, predicted VO2, HR initial, HR peak, HR 
recovery at first and third minutes, blood pressure at the start and maximum 
reached, RER, VAT and VE/VCO2 slope. 
 
EQUIPMENTS AND PROTOCOLS OF ASSESSMENT 
 
Echocardiography: resting cardiac echocardiogram was recorded in a lying 
position using a commercially available digital ultrasound scanner (Vivid 7, Vivid 
3 and Vivid IE9, GE Vingmed Ultrasound, Horten, Norway). In this exam, LVEF 
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was measured which represents the volumetric fraction of blood pumped out of 
the left ventricle which ejects via the aortic valve into the systemic circulation. 
Although this value is one of the inclusion criteria for this study, their difference 
before and after CRT indicates one of the criteria to response. 
NYHA class: the assessment was made according the table 1 on page 17. 
The classification was made by a cardiologist in the medical consultation before 
and after the implantation of CRT. 
CPET: all subjects underwent maximal symptom-limited treadmill CPET (GE 
Marquette Series 2000 treadmill and Mortara instrument, Milwaukee, USA), 
using modified Bruce Protocol. The 12-lead electrocardiogram and HR were 
recorded continuously during the test and continued for six minutes of the 
recovery period. Blood pressure was measured at rest, during the last 30 
seconds of each stage, at peak exercise and at the first, third and sixth minute 
of the recovery phase. 
In no case did altered blood pressure, arrhythmia, chest pain or 
electrocardiographic changes lead to interruption of the test, in accordance with 
international standards133. All studies were, accordingly, interrupted by 
subjective fatigue or dyspnea preventing the patient from continuing the 
exercise. No medication was discontinued before the test. 
Minute ventilation (VE in l/min) and oxygen uptake (VO2 in l/min/kg) were 
acquired breath-by-breath, using a gas analyzer. Gas analysis was preceded by 
calibration of the equipment and began three minutes prior to exercise. 
Patients were encouraged to perform exercise until the VCO2/VO2 ratio 
(RER) was ≥ 1.10. But in this type of patients it is complicated achieve that 
ratio, however, ratios under 1.10 were considered to this study. Besides RER, 
other derived variables were calculated, including ventilatory equivalent for 
oxygen (VE/ VO2). 
VO2peak was expressed as the highest VO2 attained during the final 30 
seconds of exercise134. Predicted peak VO2 and the percentages of the 
predicted values achieved were calculated by the system software. The VAT 
was determined using the V-slope method, and corrected, when necessary, 
using the VE/VO2 versus VE/VCO2 criterion and/or the end-tidal oxygen and 
carbon dioxide partial pressures method135. The VE/VCO2 slope was calculated 
30 
 
as the slope of the regression line relating VE to VCO2 during exercise, with 
data obtained over the complete duration of exercise. 
 
4.4.2 INDEPENDENT VARIABLES 
 
The implantation of CRT was the independent variable; the most common 
being the CRT-D. According to the Guidelines for cardiac pacing and CRT46, 
implantation of a CRT device is more demanding than implantation of a 
conventional pacemaker or implantable cardioverter defibrillator. Thus, 
additional laboratory, operator, and technical support were considered.  
In our study and according to the experts advise, patients with CRT should 
fulfill the following conditions: a) two or more cardiologists qualified for device 
implantation and management; (b) all physicians should possess knowledge 
and experience in haemodynamic monitoring and administration of 
cardiovascular support; (c) trained nurses and technical personnel; (d) pacing 
system analyzer and programmer of implanted device: electronic patient file is 
highly encouraged; (e) continuing medical education for physician, nurses, and 
technicians is mandatory. 
Two operators were required, especially during extraction/insertion of 
guidewires, handling of wires, sheaths, and stylets. Ideally, two nurses were 
required. One nurse monitors patient status and manages all necessary 
impellent accesses, including the urine catheter and the intravenous 
administration of drugs. A second nurse provides implant assistance by 
monitoring some variables, handling over sterile material; and positioning the 
ECG screen. 
Continuous anaesthesiological support is not obligatory, but quick 
anaesthesiological assistance must be available if a critical clinical situation 
develops. 
 
4.5 STATISTICAL ANALYSIS 
 
For statistical analysis it was used the Statistical Package for Social Science 
(SPSS 19.0 for Windows ®, SPSS Inc, Chicago, USA).  
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Efficacy of CRT was examined by comparing variables at baseline and after 
implantation of CRT. Differences between pre and post CRT were tested 
according to the variables categories, qualitative and quantitative, to evaluate 
the effect of this treatment. 
For the quantitative variables, it was used the Student’s t-test for paired 
samples if the normal distribution is assumed or the Wilcoxon signed-rank test if 
normal distribution cannot be assumed. Regarding normality and homogeneity 
of variances data was tested using Shapiro-Wilk and Levene's tests, 
respectively. Pearson χ2 test was used for comparisons of qualitative variables. 
Results were expressed as means ± standard deviation. 
The differences in quantitative variables (before CRT) between responders 
and non responders were analyzed using the Student’s t-test for independent 
samples or, when normality was not observed, the Mann-Whitney U test. 
Responders were defined by two parameters: an increase of 15% of the LVEF 
or an increase of 5% of the LVEF and a decrease of one level or more in the 
NYHA classification. 








In this chapter, the results and discussion will be described, respectively, for 
each dependent variable. Initially, the results will be referred to the baseline, 
describing their characteristics, and then the comparison will be made between 
the group of responders and non responders according to the studied variables 
before CRT. Finally, the comparisons between the studied variables before and 
after CRT on exercise performance will be described. 
 
 PARTICIPANTS CHARACTERISTICS 
 
The clinical and demographic characteristics of the study population are 
summarized in table 3. Around 75% of the patients were medicated with beta-
blockers, 60% with diuretics and 40% with angiotensin-converting enzyme 
inhibitors or/and angiotensin receptor blockers. A high percentage of patients 
had a CRT-D implanted (93%). 
 
COMPARISON BETWEEN RESPONDERS AND NON RESPONDERS 
VARIABLES 
Table 3: Clinical and demographic characteristics at baseline for the sample in the study (n=15) 
Men 11 (73.3%) 
Women 4 (26.7%) 
Age (years) 64 ± 10 (48; 81) 
BMI (kg/m
2
) 27.3 ± 5 (19.3; 36.7) 
Etiology  





Isquemic Dilated Cardiomyopathy 2 (13.3%) 
NYHA class  
III 14 (93.3%) 
IV 1 (6.7%) 
LVEF (%) 27 ± 8 (11; 38) 
Values are expressed as mean ± standard deviation (minimum; maximum) 
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According to the different classification criteria to define responders to CRT 
(either an increase of 15% of the LVEF or an increase of 5% of the LVEF and a 
decrease of one level or more in the NYHA classification), the demographic 
characteristics, the patients’ medications, echotrocardiographic values and 
functional characteristics at baseline were listed in tables 4 and 5. 
Table 4: Comparisons of baseline demographic, clinical, and functional characteristics in 
responders vs. non responders to CRT considering echocardiographic parameters 
 Responders (n=9) Non Responders (n=6) P-value 
Age (years) 63 ± 9 66 ± 12 0.644 
Men/women (n) 5/4 6/0 0.057 
































NYHA III/IV 3.11 ± 0.3 3 ± 0 0.435 
LVEF (%) 27 ± 8.4 26.7 ± 8.9 0.942 
Peak VO2 ≤ 14 ml/kg/min 4 3 0.833 
VO2(ml/kg/min) 
Peak exercise 
Percentage of predicted VO2 (%) 
 
14.7 ± 6.2 
56.4 ± 17.8 
 
17.7 ± 4.7 




VE/VCO2 slope (L/min) 30.5 ± 10.1 38.6 ± 4.4 0.200 
Anaerobic threshold (n achieve) 4 5 0.132 




112 ± 19 
143 ± 20 
 
118 ± 18 








60 ± 10 
72 ± 10 
 
68.33 ± 8 








80 ± 12 
125 ± 25 
 
92 ± 13 












14 ± 7 
38 ± 17 
 
18 ± 12 




Respiratory Exchange Ratio 0.95 ± 0.17 0.98 ± 0.11 0.935 
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Positive echocardiographic response to CRT was observed in 9 patients, 
corresponding to a 60% responder rate, as seen in table 4. No differences were 
observed between the two groups regarding demographic, clinical and 
functional characteristics, probably owing to the small study sample size. 
As we can see in table 4, the baseline characteristics of the two groups were 
overall similar, including functional capacity and echocardiographic 
measurements. 
The HR initial was lower in responders than non responders, the difference 
were 12 bpm, but did not reach statistical significance (p > 0.05). No significant 
differences were observed between patients with VO2peak ≤ 14 ml/kg/min. 
No clear-cut value was found for separating responders and non 
responders. 
Table 5: Comparisons of baseline demographic, clinical, and functional characteristics in responders 
vs. non responders to CRT considering echocardiographic and clinical parameters (Combined) 
 Responders (n=11) Non Responders (n=4)  P-value 
Age (years) 68 ± 9 55 ± 9 0.024 
Men/women (n) 7/4 4/0 0.159 
































NYHA III/IV 3.09 ± 0.3 3 ± 0 0.566 
LVEF (%) 27 ± 9 26.5 ± 7 0.922 
Peak VO2 ≤ 14 ml/kg/min (n) 6 1 0.310 
VO2(ml/kg/min) 
Peak exercise 
Percentage of predicted VO2 (%) 
 
14.3 ± 5 
56.4 ± 15.2 
 
20.4 ± 5.4 




VE/VCO2 slope (L/min) 30.6 ± 8.2 28 ± 5.7 0.975 
Anaerobic threshold (n achieve) 6 3 0.475 




114 ± 16 
140 ± 21 
 
116 ± 26 








As we can see in table 5, in the combined parameters, positive responders 
to CRT corresponding to a 26.7% non responder rate. Overall, the baseline 
characteristics of the NYHA, LVEF and SBP (both at initial and peak of CPET) 
of the two groups were similar (table 5). 
Among all variables examined, in our study, the only significant differences 
detected were the age, peak HR and HR recovery after 3 minutes from CPET 
performance. 
The mean age was significantly higher approximately 13 years in 
responders compared to non responders (p = 0,024). Whether age negatively 
affects response to CRT is currently unknown; this is an important issue, 
because most patients with HF are of greater age136. 
The peak HR before CRT was higher 39 bpm in non responders than in 
responders (p ≤ 0.05), whereas the minute 3 of HR recovery was lower 23 bpm 
in responders than in non responders before CRT (p = 0.014). In contrast to a 
previous finding, baseline HR recovery at minute 1 and 3 could not predict 
response to CRT, their values between responders and non responders were 
very similar117. In our study, this does not happen, there were different values at 
baseline. According to the literature, HR recovery immediately after exercise is 
a function of vagal reactivation, a decrease of vagal activity is known to be a 
risk factor for death114. Thus, the faster the recovery, in this case for non 
responders, there is an increase of vagal activity. 
Responders, compared with non responders, were more likely to have 
dilated cardiomyopathy heart disease (33.3% vs. 26.7%, p > 0.05), and more 
diuretic and beta blocker medications (46.7% vs. 13.3% p > 0.05 and 46.7% vs. 




60 ± 9 
70 ± 10 
70 ± 8 
75 ± 6 
0.108 
0.338 




82 ± 10 
118 ± 18 
 













13 ± 9 
31 ± 14 
 
21 ± 8 




Respiratory Exchange Ratio 0.95 ± 0.15 0.98 ± 0.14 0.732 
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The group of non responders had a VO2peak and a percentage of predicted 
VO2 higher than the group of responders although not reaching statistical 
significance (20.4 ± 5.4 ml/kg/min vs. 14.3 ± 5 ml/kg/min p = 0.058 and 67.8 ± 
7.3% vs. 56.4 ± 15.2%, p = 0.186). In a recent study, Arora et al.137 found a 
significant value for the VO2peak between responders and non responders. A 
positive responder was considered if VO2peak ≥ 1 ml/kg/min. In the non 
responder group, the value was higher than the group of responders (11.7 ± 2.4 
ml/kg/min vs. 10.6 ± 2.3 ml/kg/min p < 0.05). The percentage of predicted 
VO2peak was not significantly different between groups but was higher in the non 
responder’s group. 
As mentioned previously, patients with a baseline VO2peak < 14 ml/kg/min 
regularly benefit from CRT during the first year of treatment23. The German 
“Statement on cardiac resynchronization”25 already recommends a baseline 
VO2peak < 14 ml/kg/min as one criterion to indicate CRT. As we can observe in 
table 5, the value of the VO2peak for the responder’s group was almost < 14 
ml/kg/min, with a p = 0.058. Probably owing to the small study sample size, it 
was not possible to obtain statistically significance in the VO2peak, but there is a 
trend towards a lower VO2peak. 
The VE/VCO2 slope (30.6 ± 8.2 l/min vs. 28 ± 5.7 l/min) and the 
achievement of the VAT (n = 6 vs. n = 3) were higher in the group of responders 
than non responders, but no significant differences were found. 
 
In this study, it was possible to make a relation between the response 
criteria and their efficacy response rate according the Fornwalt review6 
mentioned previously.  In that review, the response rate for the response criteria 
parameter ≥ 15% improvement of LVEF was 54%; the response criteria for 
combined parameters was 71%, as we can see in table 2. Similar findings have 
also been demonstrated in this study, it was on the combined response criteria 








EFFECT OF CRT ON EXERCISE PERFORMANCE 
 
 
The average time lapse between the first and second echocardiograms 
(before and after CRT, respectively) was 2 months ± 18 days. 
As observed in table 6, the mean LVEF was significantly increased 
approximately 14 % (p < 0.05). One of the inclusion criteria to CRT is the LVEF 
≤ 35%, the value after CRT was higher than 35%, which indicates good improve 
of this variable. Moreover, HF patients with normal LVEF (> 50% LVEF) have a 
lower mortality risk than cases with reduced LVEF138. 
In the clinical parameter, five months after the implantation of CRT, the 
mean NYHA functional class improved significantly, it decreases to a NYHA 
class 3 to a  class 2 (p < 0.0001). It is noteworthy that our results are consistent 
with the findings of some studies12, 23, 75, 137 which demonstrates a near identical 
level of improvement on NYHA class after CRT. According to the 2010 focused 
update of the European Society of Cardiology Guidelines15 on device therapy in 
Table 6:  Patient characteristics before and after CRT 
Variable Before CRT After CRT P Value 
VO2(ml/kg/min) 
Peak exercise 
Percentage of predicted VO2 (%) 
 
15.9 ± 5.6 
60.8 ± 15 
 
16.3 ± 5.6 




VE/VCO2 slope (L/min) 34.6 ± 8.5 29.9 ± 7.5 0.241 
Anaerobic threshold (%achieve) 60 73.3 0.132 




115 ± 18 
142 ± 21.2 
 
122 ±19 








63.3 ± 9.7 
71 ± 9.3 
 
70.3 ± 12 








85 ± 13 
128 ± 24 
 
80 ± 12 












15 ± 9 
37 ± 17 
 
22 ± 11 




Respiratory Exchange Ratio 0.96 ± 0.14 1 ± 0.11 0.262 
NYHA 3.07 ± 0.26 2.2 ± 0.4 0.0001 
LVEF (%) 26.9 ± 8.3 41.3 ± 11.5 0.006 
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HF, the impact of CRT, on average, in NYHA function class is the decreased by 
0.5–0.8 points. In this study, the decrease was 0.87 points. This indicates that, 
on average, patients with marked limitation of physical activity (NYHA class 3) 
improved to slight limitation of physical activity (NYHA class 2) (table 1, page 
17). 
When comparing the HR profile during exercise, there was a significantly 
changed after CRT (table 6), beta blockers must be considered because of their 
HR lowering action32. In our study, as mentioned previously in the chapter of 
limitations, the drug therapy was sometimes collected at the time of exercise 
testing. 
The peak HR was significantly lower about 2 bpm after CRT (p < 0.05). 
Unlike other studies12, 137, the peak HR showed a decrease instead of an 
increase in our study. The exact mechanism for the restoration of a more 
physiologic increase in HR during exercise after CRT remains to be elucidated, 
but it is probably related to unloading of ventricular sensory receptors or 
improved ventricular filling capability139. 
The HR assessed at the start of the CPET decreased 5 bpm after CRT, p > 
0.05. It is not certain whether there is a long-term relation between risk of death 
associated with increased rest HR and HF. Two studies done on HF patients 
found that increased HR at baseline140, 81 was associated with worse outcome. 
The decreased HR initial may reflect increased vagal tone and decreased 
sympathetic tone after CRT, which has been associated with more favorable 
prognosis141. Sustained reduction of sympathetic activity during CRT has been 
recently demonstrated142.  
The HR recovery after the first and third minutes from the performance of 
CPET was not significantly different. However, the HR measured at minute 1 
after CPET increased 7 bpm and at minute 3 increased approximately 1 bpm. 
According to previous studies, an abnormal value for the HR recovery at minute 
1 was defined as a reduction of 12 bpm or less from the HR at peak exercise114. 
As we can see in table 6, the mean of the HR recovery at minute 1 either before 
or after CRT, were higher than 12 bpm. Some authors115, 116 conclude that HR 
recovery on the first minute recovery is a significant predictor of mortality and 
may provide valuable prognostic information for patients with HF or LVSD. This 
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indicates that, in this study, there is a tendency to be significant the HR 
recovery at minute 1 because of the improvement and the high value assessed. 
Furthermore, the importance of HR in determining exercise capacity in CRT 
patients has been investigated in a recent study and it was demonstrated that 
chronotropic incompetence is an important determinant of peak exercise 
capacity143. 
The increased peak systolic blood pressure may indicate a higher chronic 
peak cardiac output or more efficient vasoconstriction of non exercising 
vascular beds occurring after CRT12. In this study, the increased in the peak 
SBP was statistically significant, going from 142 ± 21.2 to 158 ± 27.8 p = 0.032. 
In turn, the increase of diastolic blood pressure from 63.3 ± 9.7 to 70.3 ± 12, 
was also statistically significant. The significance of this finding is unclear, 
although a slight increase in diastolic pressure may be responsible for a better 
coronary perfusion, as well as an indicator of improved arterial compliance. 
VO2peak consumption, obtained during maximal exercise testing, has been 
the gold standard to assess exercise performance. Seven patients (46.7%) had 
a baseline peak VO2 ≤ 14 ml/kg/min, one patient (6.6%) had a VO2peak ranging 
between 14 and 16 ml/kg/min, and 7 patients (46.7%) had a VO2peak ≥ 16 
ml/kg/min. Thus, these seven patients in our study that has VO2peak < 14 
ml/kg/min at baseline, regularly benefit from CRT during the first year of 
treatment according to a study23. 
Both VO2peak and percentage predicted VO2peak are similar in providing 
prognostic information in patients with advanced HF144. However, a closer 
examination of the initial exercise test showed that VO2peak increases with no 
significant difference (table 6). The percentage of predicted VO2peak was also 
not significant, it raises from 60.8 ± 15% to 63.4 ± 20% indicating that, 
according to the literature, these patients have a 94% possibility two year 
survival compared to patients with a below 50% of predicted VO2peak
20. In 
multivariate analysis, of other studies, 50% or 55% of predicted VO2peak has 
generally been selected as the most significant predictor of cardiac death121. 
The RER rises from almost 0.5 but it wasn’t significant. However, this raise 
might indicate better anaerobic metabolism and an indicator of maximal effort. 
In a study, independent predictors of mortality were different in patients with a 
RER < 1.0 compared to those with a RER ≥ 1.0. In CHF patients with a RER < 
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1.0, traditional prognostic markers (VE/VCO2 slope, VO2peak) were not 
independently predictive of mortality, conclude Ingle et al.122. By our result, it 
appears that the RER does not reach the value that indicates maximal effort. 
One possible reason to do not reach that value was that the modified Bruce 
protocol on a treadmill may be too challenging for elderly CHF patients with 
comorbidities, alternative methods of exercise testing such as a more gentle 
ramping treadmill protocol, or cycle ergometry may yield greater success for this 
type of population. Rostagno et al.145 estimated that 1 in 3 CHF patients were 
unable to perform a CPET successfully as defined by RER criteria (RER ≥ 
1.10). In this study, as we can see in tables 5, 6 and 7 the average of RER was 
always ≤ 1.10. 
By our result in this study, it appears that there is a tendency to lower the 
risk for transplantation or death after CRT. The reason for that affirmation was 
that patients with VO2peak < 11 ml/kg/min and VE/VCO2 slope ≥ 34 are at 
particularly high risk for transplantation or death129. Thus, in our study, as we 
can observed in table 6, the value of the VE/VCO2 slope increased after the 
CRT to 29.9, lesser than 34. 
It was observed that the respiratory efficiency given by the VE/VCO2 slope 
decreased after CRT (p > 0.05). The same findings were shown in previously 
studies that describe the decrease of the VE/VCO2 slope after CRT
98, 137.  
Evidence has suggested that the prognostic value of the VE/VCO2 slope 
could be greater than VO2peak, particularly for patients undergoing sub-maximal 
effort, patients treated with beta-blockers and those with LVEF less than 45%127, 
146-148. In fact, the main limitation is the frequent sub-maximal effort during 
CPET, with an underestimation of maximal VO2peak leading to the wrong 
prognostic interpretation. 
VAT was not detected in all patients, 60% achieved the threshold before the 
CRT and 73.3% after the CRT. VAT cannot be obtained in 25% to 30% of 
patients with HF because of severe deconditioning, early onset of acidosis, and 
the presence of an irregular breathing pattern132. 
The skeletal musculature in HF patients might be a reason to this severe 
deconditioning. Patients with HF are limited in their ability to tolerate exercise. 
Recent research has suggested that this limitation cannot be entirely attributed 
to cardiac or lung impairment. The peripheral muscles may play an important 
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role. HF patients have deficiencies in peripheral blood flow and skeletal muscle 
function, morphology, metabolism and function. Moreover, an exaggerated 
activity of the receptors sensitive to exercise derived metabolic signals leads to 
early and profound exercise-induced fatigue and dyspnea. These muscle 
afferents contribute to the ventilatory, haemodynamic and autonomic responses 
to exercise both in physiological and pathological conditions, including chronic 






Considering the purposes defined for the present study and the obtained 
results, we conclude that:  
1. CRT significantly increases ventilatory and haemodynamic responses 
after 5 months in some variables. Patients with an increased SBP peak, a 
higher DBP initial, increased LVEF and decreased HR peak and NYHA seem to 
benefit the most from this therapeutic approach. 
2. CPET baseline measurements can potentially be used to identify patients 
who will respond to this therapy. The comparison between responders and non 
responders in two separate classification criteria were different.  
3. The echocardiography criteria (increase of 15% of the LVEF) did not show 
any statistically significant result. On the contrary, the so called combined 
criteria definition (increase of 5% of the LVEF and a decrease of one level or 
more in the NYHA classification) has shown some significant differences.  
4. The variables that were significant were the age, HR peak and HR 
recovery at minute 3.  
Further studies are needed to document and assess these predictive 
variables to be part of the inclusion criteria in order to direct responder patients 
to benefit from CRT. 
 
CPET testing in patients with systolic HF provides noninvasive objective 
measures of cardiopulmonary reserve and is thus suitable for evaluation, risk 
stratification and control of treatment effects. Echocardiography and CPET 
parameters may be combined to define CRT inclusion criteria that will decrease 
the rate of non response. 
7 FUTURE RECOMMENDATIONS 
 
In future investigations in this topic, we consider that it will be important to 
assess how relevant in follow up will be the role of including a monitored 
physical activity, such as walking and cycling, or other leisure time and 




The protective effects of physical training have been described in many 
recent studies. It would be recommended a cardiac rehabilitation program to 
bring additional benefits for CRT patients and compare their influence in 
responders and non responders.  
 
Thus, it is important to have a continuous assessment of these patients at 3, 
6 and 12 month post procedure. This may include all the exams that were done 
before the CRT, such as CPET and Echocardiography, in order to assess the 
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